- 12 oral surgery updates in 2026
- 5 ASC, MOB deals in California
- Hidden OR capacity challenges: 8 perioperative leaders on what’s draining surgical time
- The Aspen Group’s 3-year growth recap: 40 moves
- Florida State University set to acquire Tallahassee hospital
- How Confusing Financial Journeys Undermine Revenue and Trust
- How Confusing Financial Journeys Undermine Revenue and Trust
- Misalignment, Not Malice: Rethinking Generational Conflict in Healthcare
- If AI ‘adds friction, it fails’: How Mayo Clinic scales technology
- As maternity units close, AdventHealth restores OB care in rural Kansas
- Oklahoma officials warn of new opioid
- The new metrics of healthcare technology ROI: What matters to healthcare leaders
- Hoag to launch transplant center in 2027
- MercyOne hospital to transition labor and delivery services
- MercyOne hospital to transition labor and delivery services
- Southeast metros lead US population growth as national gains slow
- 8 Medicare Advantage numbers to know in 2026
- 17 Senate Dems push back on 2027 ACA proposal
- Providence hospital closes inpatient pediatric unit
- Michigan finalizes Medicaid mental health assessment policy changes
- 10 financial notes on USPI’s growth over the past 3 years
- 15 new orthopedic practice, center openings in Q1
- The oral surgery technological revolution
- From Anxiety to Action: How Ambulatory Leaders Are Rebuilding Margins in 2026
- Where GI training may fall short
- What it took to become the world’s first ASC to offer Stryker’s robotic knee tech
- Medtronic’s win in spinal cord stimulator lawsuit upheld
- How the Trump Administration Uses Migrant Kids To Find and Detain Family Members
- Heartland Dental’s 3-year growth recap: 30+ moves
- Cencora’s $10B+ physician acquisition spree: A breakdown
- Tennessee physician practice acquired
- The FTC is coming for healthcare consolidation: 10 things physicians need to know
- Adventist Health sees momentum from insourcing revenue cycle operations
- Oral GLP-1s, COVID preventatives: 3 more drugs in the pipeline, Optum says payers should watch
- Unlicensed dentistry cases, DSO deals, legislation & more: 10 dentistry updates in Virginia
- Missouri system debuts mobile behavioral health unit
- Yale researchers study GLP-1’s potential for SUD
- Texas dental school receives $6.5M to expand pediatric dental, medical programs
- North Carolina autism provider to expand therapy access
- $3M Verdict Links Social Media to Anxiety and Depression
- West Virginia hospital to end OB delivery services
- 6 DSOs making headlines
- California hospital’s finances improve, cash position remains ‘dire’
- 1 in 5 metro markets face inpatient monopoly: 7 notes
- Minnesota system faces uncertainty amid Medicare delays
- Ohio county approves behavioral health crisis center plan
- The White House Delays CDC Pick
- New COVID 'Cicada' Variant Is Spreading — What Experts Want You To Know
- Op-ed: Empathy meets efficiency—how the responsible use of AI can transform Medicare
- Family Caregivers Provide $1 Trillion In Annual Labor, AARP Says
- ‘Health Doesn’t Need to Be Ludacris’: Bayer signs rapper-actor to multivitamin campaign
- Rocket plots measured trajectory for new gene therapy Kresladi after clearance to launch from FDA
- Healthy Lab Results May Mask Future Risks for Kids with Obesity
- At-Home Chemotherapy Is Safe, Feasible, Pilot Study Indicates
- What You Do While Sitting Could Predict Dementia Risk
- New Cholesterol Guidelines: What Patients and Caregivers Need to Know
- Want A Bootlicking Yes Man? Ask An AI Chatbot For Advice, Study Warns
- Specially Coated Implants Better For Breast Cancer Patients, Study Finds
- Trump Team Claims Successes Against ACA Fraud While Pushing for More Controls
- Give and Take: Federal Rural Health Funding Could Trigger Service Cuts
- Fierce Pharma Asia—Takeda’s $1.3B reorg; India’s GLP-1 floodgates; Gilead’s $2.2B buy of a China NewCo
- Where are you with EUDAMED?
- Where are you with EUDAMED?
- HL7 Launches Real‑Time Medical Device Interoperability Accelerator
- HL7 Launches Real‑Time Medical Device Interoperability Accelerator
- Two GA Tech ATDC Startups — Nephrodite and OrthoPreserve — Secure FDA Breakthrough Device Designation
- Two GA Tech ATDC Startups — Nephrodite and OrthoPreserve — Secure FDA Breakthrough Device Designation
- Artificial Intelligence: ROI, not Clinical Autonomy, Leads Operational Workflows
- Artificial Intelligence: ROI, not Clinical Autonomy, Leads Operational Workflows
- Medtronic and Merit Medical Systems distribution agreement for new, ViaVerte basivertebral nerve ablation system
- Medtronic and Merit Medical Systems distribution agreement for new, ViaVerte basivertebral nerve ablation system
- Breakthrough Device Designation for Noah Labs Vox Heart Failure Detection Device
- Breakthrough Device Designation for Noah Labs Vox Heart Failure Detection Device
- Why private practice dentistry needs a better model
- CareQuest Innovation Partners, Kno2 collab on medical-dental data integration
- Nonprofit highlights rural opioid care strategies
- Vitana Pediatric & Orthodontic Partners adds Florida practice
- What the Health? From KFF Health News: A Headless CDC
- 20 behavioral health leaders challenge industry assumptions
- Recordati confirms it's weighing CVC Capital buyout offer of $12.6B
- 3 California behavioral health centers to close amid funding shifts
- Indiana bars autism therapy provider from Medicaid billing: Wall Street Journal
- UnitedHealth shareholder sues over proposal to include details on integration in annual proxy
- SCAN taps biopharma, CMS vet Aman Bhandari as its first chief AI officer
- Infosys to acquire Optimum Healthcare IT in $465M deal
- DOJ alleges NewYork-Presbyterian forces payers into anticompetitive 'all-or-nothing' contracts
- FDA Warns Biotech Firm Over Cancer Drug Anktiva Claims
- Bees and Hummingbirds May Be Consuming Small Amounts of Alcohol
- Two States Sue Cord Blood Company Over Misleading Claims
- New WHO Guidance Aims To Speed Tuberculosis Testing
- As questions swirl around ATTR competition, Alnylam plots path to market leadership for Amvuttra
- Trump admin delays nomination for new CDC director past deadline
- Outspoken ACIP member steps down amid vaccine panel uncertainty: reports
- Egg-based drugmaker Neion Bio emerges from stealth to cook up multi-product biosimilar collab
- Genentech walks the walk in lupus as sponsor of annual awareness and fundraising event
- Study Reveals How Many Americans Consider Using a Gun
- Massive Study Finds Stress and Grief Don’t Cause Cancer
- Ultra-Processed Foods Harm Fertility In Both Men And Women, Studies Reveal
- Small Daily Habits Can Add Up To Better Heart Health
- Ritalin Might Protect ADHD Kids' Long-Term Mental Health, Study Finds
- Can You Drink Enough Fluids To Prevent Kidney Stones? Maybe Not, New Study Says
- Clasp, loan-linked hiring tool for employers, clinches $20M to expand amid federal loan caps
- Taking a GLP-1? Doctors Say Not To Forget About Movement and Mental Health
- OpenEvidence rolls out AI medical coding feature
- CDC’s Acting Chief Promises a Return to Stability in a Tumultuous Moment
- Remarks at the Financial Stability Oversight Council Meeting
- RWJF: Between 5M and 10M people could lose Medicaid coverage in 2028 under work requirements
- New therapy animal program aims to support 100K patients, providers
- Pulse check on Lilly's GLP-1 fortunes
- Gen Z nurses prioritize schedule flexibility, need more manager interactions to avoid turnover
- How pharma marketers can capitalize on HCPs’ AI, social media and streaming habits
- Federal Officials Investigate States That Require Abortion Coverage
- Corcept's lead drug bounces back from FDA snub with different approval as Lifyorli in ovarian cancer
- Ionis slashes Tryngolza's price tag by 93% ahead of anticipated label expansion
- FDA approves Denali's Hunter syndrome drug, handing rare disease community a win
- Baby Walkers Sold on Amazon Recalled Over Fall Risk
- Want To Protect Your Brain? Science Says Exercise
- HelloFresh Pizza Recall Issued in 10 States Over Metal Risk
- Clinical Trials Have Too Much Data…That’s the Problem.
- Clinical Trials Have Too Much Data…That’s the Problem.
- CMS reveals new Medicaid model that supports coordination for children with complex needs
- Novartis sued by breast cancer patient over branded drug websites’ data-sharing practices
- Takeda targets $1.3B in cost savings in further restructuring
- Biogen pays $20M upfront to tap into Alteogen's subQ delivery tech
- 'Universal Donor' Blood Supplies Dangerously Low, Study Warns
- Why Stepping Outside May Help You Eat Better
- U.S. Medicine, Science Facing An Online Misinformation Siege, Poll Concludes
- Childhood Obesity Undercuts The American Dream For Some, Study Says
- Inclusive High Schools Benefit All Students, Not Just LGBTQ Teens
- Parental Loss Due to Drugs, Violence Raises Child Death Risk by 2,000%
- As Boehringer touts US launches, board chairman worries EU is 'falling further behind'
- The evolving state of exome and genome sequencing
- Demoralized CDC Workforce Reels From Year of Firings, Funding Cuts, and a Shooting
- An Arm and a Leg: Steep Health Care Costs Steer Americans to Tough Decisions
- Qualified Health locks in $125M in fresh funding to scale enterprise AI at health systems
- Misery Loves [Investment] Company?: Remarks at the 2026 Investment Company Institute Investment Management Conference
- Study: Nearly 1 in 5 pediatric hospital deaths involve sepsis
- As expansions come online, CDMO Hovione aims to meet industry's 'dual supply and sourcing' zeal: exec
- Opening Remarks at the Digital Asset Summit 2026
- CVS Caremark, FTC reach settlement in insulin pricing case
- UCB unveils plan to build $2B biologics plant near its US headquarters in Atlanta
- PeaceHealth sued over plans to tap out-of-state staffer ApolloMD for Oregon EDs
- New Lyme Disease Vaccine Shows Strong Results in Trial
- TrumpRx Adds Diabetes, COPD Drugs at Steep Discounts
- Highmark reports $175M net loss for 2025 as financial headwinds batter health plan
- Listen to the Latest ‘KFF Health News Minute’
- Abivax hires commercial chief from Takeda to infuse Entyvio expertise into IBD launch prep
- ImmunityBio hit with FDA warning letter over Anktiva promotions in TV ad, podcast episode
- Alcohol Prep Pads Recalled Over Bacteria Risk, Cardinal Health Says
- Fewer patients traveled for abortions in 2025 as telehealth care increased, report finds
Obviously, these "behavioral science" results aren't to be trusted. The really tricky policy question is identifying the special interest behind it. Who benefits from skewing this data?
And the real-world conundrum: how much "behavioral health science" is also on shaky ground?
Francesca Gino, a prominent Harvard Business School professor, alleged to have falsified results in behavioral science studiesOver the last few weeks, allegations have surfaced against Francesca Gino, a prominent Harvard Business School (HBS) professor who has been accused of falsifying results in several behavioral science studies.
On 16 June, the Chronicle of Higher Education reported that Max Bazerman, a HBS professor and co-author who published a paper in 2012 alongside Gino, said that Harvard informed him that it believed one of the studies overseen by Gino had falsified results.
The paper in question is on findings published in – and later retracted by – the Proceedings of the National Academy of Sciences and surrounds an experiment that asked participants to fill out tax and insurance paperwork.
“Many written forms required by businesses and governments rely on honest reporting. Proof of honest intent is typically provided through signature at the end of, eg, tax returns or insurance policy forms. Still, people sometimes cheat to advance their financial self-interests at great costs to society. We test an easy-to-implement method to discourage dishonesty: signing at the beginning rather than at the end of a self-report, thereby reversing the order of the current practice,” the paper’s abstract read.
The study claimed to have discovered that participants who were asked to sign truthfulness declarations at the top of the page were more honest than those who were asked to sign the declarations at the bottom of the page.
According to the Chronicle of Higher Education, Bazerman said that the university provided a 14-page document that included “compelling evidence” of data falsification, including the discovery that someone accessed a database and added and altered data in the file. He went on to deny any involvement in the alleged data tampering, telling the Chronicle: “I did not have anything to do with the fabrication.”
A day later, a blog called DataColada and run by three behavioral science academics published a four-part series of posts that detailed extensive evidence of the alleged fraud in four academic papers co-authored by Gino.
“We discovered evidence of fraud in papers spanning over a decade, including papers published quite recently (in 2020),” the blog authors, ESADE Business School’s Uri Simonsohn, University of California, Berkeley’s Leif Nelson, and University of Pennsylvania’s Joseph Simmons, wrote.
“In the fall of 2021, we shared our concerns with Harvard Business School. Specifically, we wrote a report about four studies for which we had accumulated the strongest evidence of fraud. We believe that many more Gino-authored papers contain fake data. Perhaps dozens,” the scholars said.
“We understand that Harvard had access to much more information than we did, including, where applicable, the original data collected using Qualtrics survey software. If the fraud was carried out by collecting real data on Qualtrics and then altering the downloaded data files, as is likely to be the case for three of these papers, then the original Qualtrics files would provide airtight evidence of fraud. (Conversely, if our concerns were misguided, then those files would provide airtight evidence that they were misguided),” they added.
To the best of their knowledge, none of Gino’s co-authors carried out or assisted with the data collection for the studies in question, the scholars said.
According to Gino’s HBS profile, she is currently on administrative leave.
Speaking to the New York Times, a man who identified himself as Gino’s husband said: “It’s obviously something that is very sensitive that we can’t speak to now.”
Faulty tools, faulty results.
Today Morning Brew delivers a concise description of the Excel flaw that skewed gene studies.
Microsoft updates Excel feature that caused problems for scientists
The feature, known as Automatic Data Conversion, converted certain human gene names into dates and created massive errors in scientific research.
Microsoft is finally tweaking an Excel feature that has caused nearly two decades of grief for scientists. The feature, known as Automatic Data Conversion, which in the past constantly converted certain human gene names into dates and created massive errors in scientific research, can now be disabled.
If your science background is more Intro to Geology…every one of the nearly 44,000 human genes has a shortened version of its name and a symbol. So when a scientist typed SEPT1 to represent the Septin-1 gene in an Excel sheet, the program would assume they meant September 1 and change it. And if you’ve ever been the dogsbody who has to comb through an Excel file, you know it’s easy to miss a tiny error like this.
But those tiny errors amounted to big problems: A study of 10,000 scientific papers on genes published from 2014–2020 found that more than 30% contained a gene name error that was Excel's fault. It got so bad that by 2020 the governing body behind gene naming had updated 27 gene names so they couldn’t be mistaken in the Microsoft program (i.e. SEPT1 became SEPTIN1).
How to turn it off: You can now personalize Excel’s auto correcting functions under File>Options>Data.
https://www.morningbrew.com/daily/stories/updates-excel-caused-problems-scientists30% in 17 years.
3,000 papers in genes. That's a lot of research, and it touches a lot of lives.
Wonder how many drugs were impacted?
Is this part of the reason for the pre/post-release discrepancies in so many drugs?
Is the current rush to capture all Sickle Cell carriers founded on any of these errors?
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.

















